title: Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever.
abstract: The aim of the study was to determine the economical impact of juvenile idiopathic arthritis (JIA) and familial Mediterranean fever (FMF) in Turkey. A total of 100 patients (69 F/31 M) with JIA and 100 with FMF (68 F/32 F) who were consecutively seen in the outpatient clinic of the pediatric rheumatology department at Cerrahpasa Medical School between August 2008 and January 2009 were studied. Cost data were collected through a questionnaire filled out by the parents. The mean age (JIA: 11 ± 5 years; FMF:12 ± 4 years) and mean disease duration (JIA:5 ± 3 years; FMF: 4 ± 3 years) of the patients were similar. JIA patients were assigned to 5 subtypes (polyarticular: n = 45, oligoarticular: n = 30, systemic onset: n = 13, psoriatic: n = 6, and enthesopathy-related JIA: n = 6). Forty-nine percent of the patients with JIA were treated with anti-TNF drugs and 61% with DMARDs. All patients with FMF were using colchicine. The total annual cost of JIA (<euro>3,994 ± 4,101) was considerably higher than that of FMF (<euro>162 ± 77) (P < 0.001). Medication fee was the major determinant of total costs in both diseases constituting 85% in JIA and 39% in FMF. Among the subtypes of JIA, total annual costs were the highest among patients with polyarticular type (<euro>6,045 ± 4,078). Medications especially anti-TNF drugs were the major contributor among all determinants of costs in JIA. The low costs of health care system and prominent changes in the health care policies for the last 5 years in Turkey might have played role in our findings.
authors: Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
authors: Ilker Kemal
authors: IK
authors: Yucel
authors: Emire
authors: E
authors: Seyahi
authors: Ozgur
authors: O
authors: Kasapcopur
authors: Nil
authors: N
authors: Arisoy
mesh_terms: D000293:Adolescent; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy / Q000191:economics*; D002648:Child; D003078:Colchicine / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000191:economics; D010505:Familial Mediterranean Fever / Q000188:drug therapy / Q000191:economics*; D005260:Female; D005102:Health Expenditures; D006801:Humans; D008297:Male; D050257:Tubulin Modulators / Q000191:economics / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014421:Turkey
chemical_list: D018501:Antirheumatic Agents; D050257:Tubulin Modulators; D014409:Tumor Necrosis Factor-alpha; D003078:Colchicine